Novo Nordisk received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its oral semaglutide pill, Wegovy.
The recommendation supports obesity treatment and long-term weight management for overweight adults. Patients must have at least one weight-related condition to qualify for the treatment.
This decision positions the pill to become the first oral GLP-1 treatment for obesity in the European Union. The CHMP's opinion also incorporates data demonstrating a reduction in the risk of major adverse cardiovascular events.
The European Commission will make the final decision on marketing authorization following this recommendation.